Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | INCY |
---|---|---|
09:32 ET | 20088 | 82.685 |
09:33 ET | 34196 | 83.27 |
09:35 ET | 8188 | 82.9263 |
09:37 ET | 2600 | 82.94 |
09:39 ET | 38789 | 82.88 |
09:42 ET | 13870 | 83.01 |
09:44 ET | 19419 | 82.65 |
09:46 ET | 8778 | 82.975 |
09:48 ET | 6352 | 83.11 |
09:50 ET | 13347 | 83.29 |
09:51 ET | 7239 | 83.31 |
09:53 ET | 20516 | 83.525 |
09:55 ET | 5087 | 83.36 |
09:57 ET | 10821 | 83.24 |
10:00 ET | 7422 | 83.5 |
10:02 ET | 7473 | 83.27 |
10:04 ET | 7904 | 83.16 |
10:06 ET | 8163 | 83.15 |
10:08 ET | 2982 | 82.98 |
10:09 ET | 5223 | 83 |
10:11 ET | 7300 | 82.92 |
10:13 ET | 10790 | 82.785 |
10:15 ET | 4097 | 82.72 |
10:18 ET | 15852 | 82.805 |
10:20 ET | 3939 | 82.68 |
10:22 ET | 1956 | 82.78 |
10:24 ET | 20095 | 82.54 |
10:26 ET | 3739 | 82.55 |
10:27 ET | 2670 | 82.335 |
10:29 ET | 3931 | 82.32 |
10:31 ET | 5120 | 82.15 |
10:33 ET | 7199 | 82.58 |
10:36 ET | 3113 | 82.58 |
10:38 ET | 2892 | 82.735 |
10:40 ET | 3715 | 82.82 |
10:42 ET | 2310 | 82.75 |
10:44 ET | 2712 | 82.85 |
10:45 ET | 8808 | 82.89 |
10:47 ET | 3306 | 82.74 |
10:49 ET | 11463 | 82.795 |
10:51 ET | 1100 | 82.88 |
10:54 ET | 5453 | 82.91 |
10:56 ET | 5121 | 82.85 |
10:58 ET | 3466 | 82.85 |
11:00 ET | 5388 | 82.785 |
11:02 ET | 2905 | 82.71 |
11:03 ET | 7346 | 82.637 |
11:05 ET | 3802 | 82.78 |
11:07 ET | 10212 | 82.67 |
11:09 ET | 1222 | 82.72 |
11:12 ET | 904 | 82.77 |
11:14 ET | 2589 | 82.665 |
11:16 ET | 3410 | 82.685 |
11:18 ET | 3181 | 82.685 |
11:20 ET | 2061 | 82.625 |
11:21 ET | 1580 | 82.72 |
11:23 ET | 13701 | 82.82 |
11:25 ET | 1900 | 82.86 |
11:27 ET | 5444 | 82.862 |
11:30 ET | 1303 | 82.88 |
11:32 ET | 3182 | 82.87 |
11:34 ET | 2311 | 82.97 |
11:36 ET | 6061 | 83.04 |
11:38 ET | 2826 | 82.99 |
11:39 ET | 14991 | 83.025 |
11:41 ET | 6819 | 83.055 |
11:43 ET | 332 | 83.04 |
11:45 ET | 7723 | 82.9975 |
11:48 ET | 4352 | 83.03 |
11:50 ET | 15704 | 83.13 |
11:52 ET | 3832 | 83.19 |
11:54 ET | 5351 | 83.38 |
11:56 ET | 8707 | 83.425 |
11:57 ET | 2842 | 83.41 |
11:59 ET | 2132 | 83.44 |
12:01 ET | 1238 | 83.515 |
12:03 ET | 3428 | 83.615 |
12:06 ET | 3255 | 83.51 |
12:08 ET | 1868 | 83.505 |
12:10 ET | 901 | 83.465 |
12:12 ET | 3108 | 83.35 |
12:14 ET | 1217 | 83.255 |
12:15 ET | 2773 | 83.265 |
12:17 ET | 2626 | 83.295 |
12:19 ET | 1756 | 83.3 |
12:21 ET | 25208 | 83.69 |
12:24 ET | 3970 | 83.65 |
12:26 ET | 277 | 83.62 |
12:28 ET | 6937 | 83.38 |
12:30 ET | 2209 | 83.39 |
12:32 ET | 898 | 83.29 |
12:33 ET | 1064 | 83.315 |
12:35 ET | 2062 | 83.285 |
12:37 ET | 3265 | 83.13 |
12:39 ET | 4008 | 83.195 |
12:42 ET | 2358 | 83.17 |
12:44 ET | 887 | 83.18 |
12:46 ET | 2632 | 83.2 |
12:48 ET | 3643 | 83.18 |
12:50 ET | 600 | 83.2 |
12:51 ET | 4074 | 83.17 |
12:53 ET | 7294 | 83.3 |
12:55 ET | 3414 | 83.38 |
12:57 ET | 22575 | 83.39 |
01:00 ET | 2073 | 83.375 |
01:02 ET | 1600 | 83.39 |
01:04 ET | 700 | 83.38 |
01:06 ET | 527 | 83.45 |
01:08 ET | 3958 | 83.5434 |
01:09 ET | 2087 | 83.53 |
01:11 ET | 2931 | 83.5 |
01:13 ET | 1580 | 83.42 |
01:15 ET | 1268 | 83.42 |
01:18 ET | 4951 | 83.34 |
01:20 ET | 1279 | 83.4 |
01:22 ET | 3541 | 83.34 |
01:24 ET | 3135 | 83.28 |
01:26 ET | 2329 | 83.2316 |
01:27 ET | 800 | 83.16 |
01:29 ET | 1027 | 83.07 |
01:31 ET | 8314 | 82.99 |
01:33 ET | 3659 | 83.21 |
01:36 ET | 3161 | 83.22 |
01:38 ET | 16580 | 83.42 |
01:40 ET | 521 | 83.395 |
01:42 ET | 989 | 83.4 |
01:44 ET | 4133 | 83.36 |
01:45 ET | 9235 | 83.23 |
01:47 ET | 6554 | 83.235 |
01:49 ET | 2800 | 83.25 |
01:51 ET | 2630 | 83.215 |
01:54 ET | 3286 | 83.16 |
01:56 ET | 914 | 83.11 |
01:58 ET | 4166 | 83.15 |
02:00 ET | 1126 | 83.17 |
02:02 ET | 800 | 83.05 |
02:03 ET | 2300 | 83.01 |
02:05 ET | 1579 | 83.03 |
02:07 ET | 1202 | 83.03 |
02:09 ET | 600 | 83.07 |
02:12 ET | 660 | 83.02 |
02:14 ET | 700 | 82.97 |
02:16 ET | 600 | 82.99 |
02:18 ET | 13519 | 83.05 |
02:20 ET | 841 | 83.08 |
02:21 ET | 612 | 83.15 |
02:23 ET | 2399 | 83.27 |
02:25 ET | 2151 | 83.425 |
02:27 ET | 4142 | 83.46 |
02:30 ET | 5174 | 83.5 |
02:32 ET | 2170 | 83.615 |
02:34 ET | 10923 | 83.595 |
02:36 ET | 3792 | 83.68 |
02:38 ET | 3740 | 83.73 |
02:39 ET | 3899 | 83.75 |
02:41 ET | 1913 | 83.74 |
02:43 ET | 2200 | 83.71 |
02:45 ET | 1506 | 83.74 |
02:48 ET | 9091 | 83.814 |
02:50 ET | 8797 | 83.78 |
02:52 ET | 3397 | 83.85 |
02:54 ET | 2100 | 83.83 |
02:56 ET | 3239 | 83.83 |
02:57 ET | 7045 | 83.935 |
02:59 ET | 1242 | 83.88 |
03:01 ET | 1132 | 83.82 |
03:03 ET | 17491 | 83.735 |
03:06 ET | 3200 | 83.82 |
03:08 ET | 3927 | 83.95 |
03:10 ET | 4049 | 83.78 |
03:12 ET | 27146 | 83.65 |
03:14 ET | 1000 | 83.55 |
03:15 ET | 3427 | 83.6 |
03:17 ET | 3029 | 83.56 |
03:19 ET | 3476 | 83.465 |
03:21 ET | 1143 | 83.44 |
03:24 ET | 5054 | 83.54 |
03:26 ET | 1733 | 83.63 |
03:28 ET | 9195 | 83.68 |
03:30 ET | 2709 | 83.66 |
03:32 ET | 1300 | 83.65 |
03:33 ET | 3133 | 83.58 |
03:35 ET | 6200 | 83.63 |
03:37 ET | 4898 | 83.66 |
03:39 ET | 4598 | 83.68 |
03:42 ET | 3400 | 83.675 |
03:44 ET | 7181 | 83.7 |
03:46 ET | 3866 | 83.69 |
03:48 ET | 21066 | 83.63 |
03:50 ET | 8915 | 83.8 |
03:51 ET | 24341 | 83.72 |
03:53 ET | 9591 | 83.6 |
03:55 ET | 27105 | 83.4 |
03:57 ET | 40451 | 83.31 |
04:00 ET | 736636 | 83.38 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Incyte Corp | 16.1B | 595.8x | +39.11% |
Charles River Laboratories International Inc | 11.0B | 26.9x | +15.57% |
United Therapeutics Corp | 18.3B | 18.0x | +8.22% |
BioMarin Pharmaceutical Inc | 12.8B | 40.3x | --- |
Exact Sciences Corp | 9.5B | -43.9x | --- |
Beigene Ltd | 23.0B | -40.5x | --- |
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.1B |
---|---|
Revenue (TTM) | $4.1B |
Shares Outstanding | 192.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.72 |
EPS | $0.14 |
Book Value | $23.14 |
P/E Ratio | 595.8x |
Price/Sales (TTM) | 3.9 |
Price/Cash Flow (TTM) | 133.0x |
Operating Margin | -1.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.